Furthermore, there may be significant key differences between individuals using metformin who have contact with the secondary health care sector and those who do not, potentially leading to confounding.
← all excerpts
The use of metformin and risk of myeloproliferative neoplasms among patients with no registered markers of diabetes.
1
—
—